Fifth AMENDMENT TO CREDIT AGREEMENTCredit Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This Fifth AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of January 31, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (the “Borrower”), the other Creditor Obligors party hereto and ROS Acquisition Offshore LP, a Cayman Islands exempted limited partnership (in its capacity as Lender and Collateral Agent, the “Lender”).
SECURITIES PURCHASE AGREEMENT AMONG UNILIFE CORPORATION, UNILIFE MEDICAL SOLUTIONS, INC. AND AMGEN INC. DATED AS OF FEBRUARY 22, 2016Securities Purchase Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This SECURITIES PURCHASE AGREEMENT (as amended from time to time, this “Agreement”) is made and entered into as of February 22, 2016, among Unilife Corporation, a Delaware corporation (the “Company”), Unilife Medical Solutions, Inc., a Delaware corporation (“Unilife Medical” and, together with the Company, the “Company Parties”), and Amgen Inc., a Delaware corporation (the “Purchaser”). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 9 hereof.
Re: Amendment of Exclusivity Letter Ladies and Gentlemen:Exclusivity Letter • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus
Unilife Corporation (“Unilife”) and Amgen Inc. (“Amgen” and, together with Unilife, the “Parties”) have entered into an exclusivity letter agreement dated December 31, 2015 (the “Exclusivity Letter”). Capitalized terms used but not defined in this letter shall have the meanings assigned to such terms in the Exclusivity Letter.
Sixth AMENDMENT TO CREDIT AGREEMENTCredit Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This Sixth AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of February 9, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (the “Borrower”), the other Creditor Obligors party hereto and ROS Acquisition Offshore LP, a Cayman Islands exempted limited partnership (in its capacity as Lender and Collateral Agent, the “Lender”).
Fifth AMENDMENT TO Royalty AGREEMENTRoyalty Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This Fifth AMENDMENT TO Royalty AGREEMENT (this “Amendment”) is effective as of February 16, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (“Unilife”) and Royalty OPPORTUNITIES S.À R.L, a Luxembourg société à responsabilité limitée (together with its Affiliates, successors, transferees and assignees, “ROS”).
Seventh AMENDMENT TO CREDIT AGREEMENTCredit Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This Seventh AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of February 16 , 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (the “Borrower”), the other Creditor Obligors party hereto and ROS Acquisition Offshore LP, a Cayman Islands exempted limited partnership (in its capacity as Lender and Collateral Agent, the “Lender”).
Fourth AMENDMENT TO Royalty AGREEMENTRoyalty Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This Fourth AMENDMENT TO Royalty AGREEMENT (this “Amendment”) is effective as of February 9, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (“Unilife”) and Royalty OPPORTUNITIES S.À R.L, a Luxembourg société à responsabilité limitée (together with its Affiliates, successors, transferees and assignees, “ROS”).
EIGHTH AMENDMENT TO CREDIT AGREEMENTCredit Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This EIGHTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of February 22, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (the “Borrower”), the other Creditor Obligors party hereto and ROS Acquisition Offshore LP, a Cayman Islands exempted limited partnership (in its capacity as Lender and Collateral Agent, the “Lender”).
Third AMENDMENT TO Royalty AGREEMENTRoyalty Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This Third AMENDMENT TO Royalty AGREEMENT (this “Amendment”) is effective as of January 29, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (“Unilife”) and Royalty OPPORTUNITIES S.À R.L, a Luxembourg société à responsabilité limitée (together with its Affiliates, successors, transferees and assignees, “ROS”).
Sixth AMENDMENT TO Royalty AGREEMENTRoyalty Agreement • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus • New York
This Sixth AMENDMENT TO Royalty AGREEMENT (this “Amendment”) is entered into as of February 22, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (“Unilife”) and Royalty OPPORTUNITIES S.À R.L, a Luxembourg société à responsabilité limitée (together with its Affiliates, successors, transferees and assignees, “ROS”).
Re: Amendment of Exclusivity Letter Ladies and Gentlemen:Exclusivity Letter • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus
Unilife Corporation (“Unilife”) and Amgen Inc. (“Amgen” and, together with Unilife, the “Parties”) entered into an exclusivity letter agreement dated December 31, 2015 (the “Exclusivity Letter”). Capitalized terms used but not defined in this letter shall have the meanings assigned to such terms in the Exclusivity Letter.
Amgen Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 Attention: Corporate Secretary Re: Amendment of Exclusivity Letter Ladies and Gentlemen:Exclusivity Letter • October 24th, 2016 • Unilife Corp • Surgical & medical instruments & apparatus
Unilife Corporation (“Unilife”) and Amgen Inc. (“Amgen” and, together with Unilife, the “Parties”) have entered into an exclusivity letter agreement dated December 31, 2015 (the “Exclusivity Letter”). Capitalized terms used but not defined in this letter shall have the meanings assigned to such terms in the Exclusivity Letter.
